UY33393A - Una composición farmacéutica de liberación controlada de losartan - Google Patents

Una composición farmacéutica de liberación controlada de losartan

Info

Publication number
UY33393A
UY33393A UY0001033393A UY33393A UY33393A UY 33393 A UY33393 A UY 33393A UY 0001033393 A UY0001033393 A UY 0001033393A UY 33393 A UY33393 A UY 33393A UY 33393 A UY33393 A UY 33393A
Authority
UY
Uruguay
Prior art keywords
losartan
pharmaceutical composition
controlled liberation
controlled release
controlled
Prior art date
Application number
UY0001033393A
Other languages
English (en)
Inventor
Antonio Sereno Guerra
Loeches Blas David
Varas Fernandez-Molina Roberto
Del Cura Medina Estibaliz
Rizo Martinez Jose Miguel
Original Assignee
Liconsa Laboratorios Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liconsa Laboratorios Sa filed Critical Liconsa Laboratorios Sa
Publication of UY33393A publication Critical patent/UY33393A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de liberación controlada de losartan que comprende un núcleo de retención gástrica con losartan y una cantidad comprendida entre 5 y 25% en peso de hidroxipropilmetilcelulosa como único polímero de liberación controlada, y una capa activa de liberación inmediata que contiene losartan, a su procedimiento de preparación y a su uso para la profilaxis y el tratamiento de la hipertensión
UY0001033393A 2010-05-21 2011-05-17 Una composición farmacéutica de liberación controlada de losartan UY33393A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382135A EP2392318A1 (en) 2010-05-21 2010-05-21 A pharmaceutical controlled release composition of losartan

Publications (1)

Publication Number Publication Date
UY33393A true UY33393A (es) 2011-12-30

Family

ID=42635468

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033393A UY33393A (es) 2010-05-21 2011-05-17 Una composición farmacéutica de liberación controlada de losartan

Country Status (7)

Country Link
EP (2) EP2392318A1 (es)
AR (1) AR081400A1 (es)
BR (1) BR112012029565A2 (es)
MX (1) MX2012013362A (es)
TW (1) TW201201800A (es)
UY (1) UY33393A (es)
WO (1) WO2011144724A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002673A1 (en) * 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107789326A (zh) * 2016-08-29 2018-03-13 北京科信必成医药科技发展有限公司 一种氢氯噻嗪微片及其制备方法
IT201800011123A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione cronotropica di sartani

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008054123A1 (en) * 2006-10-30 2008-05-08 Hanall Pharmaceutical Company, Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
AR081400A1 (es) 2012-08-29
EP2571495A1 (en) 2013-03-27
WO2011144724A1 (en) 2011-11-24
EP2392318A1 (en) 2011-12-07
MX2012013362A (es) 2013-05-01
TW201201800A (en) 2012-01-16
BR112012029565A2 (pt) 2016-12-13

Similar Documents

Publication Publication Date Title
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
PA8841901A1 (es) Compuestos orgánicos
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
CL2012002880A1 (es) Compuestos derivados de pirrolobenzodiazepinas conjugados, entre otros con anticuerpos; procedimiento de preparación de un conjugado; composicion farmaceutica: procedimiento de tratamiento de cancer; y su uso para proporcionar el compuesto a una localizacion diana que es una poblacion celular proliferativa; articulo de fabricacion
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
UY31228A1 (es) Ariloxazoles sustituidos y su uso
GT201400111A (es) Triazolopiridinas sustituidas
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
DOP2014000051A (es) Imidazopiridazinas sustituidas con amino
ECSP099620A (es) Derivados de ciclohexano espirociclico
CR20120317A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101596A1 (ru) Композиция для непрерывной доставки лекарственного средства, содержащая геополимерное связующее
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210602